PL3828193T3 - Postać krystaliczna związku proleku lanosterolu i jej zastosowanie - Google Patents

Postać krystaliczna związku proleku lanosterolu i jej zastosowanie

Info

Publication number
PL3828193T3
PL3828193T3 PL19841413.8T PL19841413T PL3828193T3 PL 3828193 T3 PL3828193 T3 PL 3828193T3 PL 19841413 T PL19841413 T PL 19841413T PL 3828193 T3 PL3828193 T3 PL 3828193T3
Authority
PL
Poland
Prior art keywords
application
crystal form
prodrug compound
lanosterol prodrug
lanosterol
Prior art date
Application number
PL19841413.8T
Other languages
English (en)
Inventor
Yizhi Liu
Yandong Wang
Xiaolin Li
Zhi LUO
Haiying He
Jian Li
Shuhui Chen
Original Assignee
Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. filed Critical Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.
Publication of PL3828193T3 publication Critical patent/PL3828193T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19841413.8T 2018-07-25 2019-07-25 Postać krystaliczna związku proleku lanosterolu i jej zastosowanie PL3828193T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810826425 2018-07-25
PCT/CN2019/097773 WO2020020306A1 (zh) 2018-07-25 2019-07-25 一种羊毛甾醇前药化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
PL3828193T3 true PL3828193T3 (pl) 2025-06-23

Family

ID=69180373

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19841413.8T PL3828193T3 (pl) 2018-07-25 2019-07-25 Postać krystaliczna związku proleku lanosterolu i jej zastosowanie

Country Status (19)

Country Link
US (1) US11149055B2 (pl)
EP (1) EP3828193B1 (pl)
JP (1) JP7046266B2 (pl)
KR (1) KR102788262B1 (pl)
CN (1) CN112543762B (pl)
AU (1) AU2019308940B2 (pl)
BR (1) BR112021001172A2 (pl)
CA (1) CA3107361C (pl)
CO (1) CO2021000932A2 (pl)
ES (1) ES3025192T3 (pl)
MA (1) MA53397A (pl)
MX (1) MX2021000900A (pl)
MY (1) MY208088A (pl)
PH (1) PH12021550182A1 (pl)
PL (1) PL3828193T3 (pl)
RU (1) RU2766088C1 (pl)
SG (1) SG11202100665WA (pl)
WO (1) WO2020020306A1 (pl)
ZA (1) ZA202100923B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020177714A1 (zh) * 2019-03-04 2020-09-10 中山大学中山眼科中心 一种羊毛甾醇前药化合物的组合物及其制备方法和应用
KR102730723B1 (ko) * 2020-08-06 2024-11-18 (주)카보엑스퍼트 이노토디올 에스테르 유도체 전구 약물
WO2023020535A1 (zh) * 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
CA3228588A1 (en) * 2021-08-18 2023-02-23 Yandong Wang Pharmaceutical composition, preparation method therefor and application thereof
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN118176004A (zh) * 2022-01-28 2024-06-11 广州润尔眼科生物科技有限公司 甾体化合物在预防和/或治疗白内障中的应用
CA3243794A1 (en) * 2022-02-07 2023-08-10 Livful Inc PREPARATION OF NEW TRITERPENE ALCOHOL DERIVATIVES WITH IMPROVED BIOAVAILABILITY FOR THE TREATMENT OF CANCER, INFLAMMATION AND PAIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757062A (en) 1985-11-01 1988-07-12 E. I. Du Pont De Nemours And Company Substituted benzoate ester prodrugs of estrogens
DE3540702A1 (de) 1985-11-16 1987-05-21 Bayer Ag 1h-pyrido-(2,3-b) (1,4)-thiazine
RU2283318C1 (ru) * 2005-02-24 2006-09-10 Любовь Степановна Ермолова Способ производства стеринов: ланостерола и холестерола из шерстного жира
US20170239273A1 (en) * 2014-08-22 2017-08-24 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
SG11201701377YA (en) 2014-08-22 2017-03-30 Kang Zhang Compositions and methods to treat vision disorders
EP3536698B1 (en) * 2017-01-25 2021-08-04 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Lanosterol prodrug compound and use thereof

Also Published As

Publication number Publication date
EP3828193A1 (en) 2021-06-02
BR112021001172A2 (pt) 2021-04-27
SG11202100665WA (en) 2021-02-25
MY208088A (en) 2025-04-14
MX2021000900A (es) 2021-06-15
ES3025192T3 (en) 2025-06-06
CA3107361A1 (en) 2020-01-30
EP3828193C0 (en) 2025-03-26
JP2021524499A (ja) 2021-09-13
KR102788262B1 (ko) 2025-03-27
AU2019308940B2 (en) 2024-02-08
WO2020020306A1 (zh) 2020-01-30
CO2021000932A2 (es) 2021-02-17
US20210246158A1 (en) 2021-08-12
EP3828193B1 (en) 2025-03-26
KR20210038596A (ko) 2021-04-07
EP3828193A4 (en) 2022-06-29
CN112543762B (zh) 2022-11-08
JP7046266B2 (ja) 2022-04-01
ZA202100923B (en) 2021-10-27
US11149055B2 (en) 2021-10-19
RU2766088C1 (ru) 2022-02-07
MA53397A (fr) 2021-06-02
PH12021550182A1 (en) 2022-02-21
CN112543762A (zh) 2021-03-23
AU2019308940A1 (en) 2021-03-11
CA3107361C (en) 2022-03-22

Similar Documents

Publication Publication Date Title
ZA202100923B (en) Crystal form of lanosterol prodrug compound and application thereof
IL279468A (en) Crystallographic modifications of odeviccibat
IL273831A (en) Crystal forms and preparations of CFTR modulators
SG11202106304RA (en) Irreversible inhibitors of menin-mll interaction
ZA201904124B (en) Lanosterol prodrug compound and preparation method therefor and use thereof
IL287472A (en) Crystalline form of wee1 inhibitory compound and use thereof
IL285117A (en) Methods for characterizing properties related to condensation of compounds and their uses
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
SG11202103134TA (en) Nitroxoline prodrug and use thereof
EP3687514A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING STAT3
PL3867446T3 (pl) Kompozycje kleju do cylindra typu yankee i sposoby użycia tych kompozycji
GB2589398B (en) Compounds and methods of use
ZA202101589B (en) Crystal form of tri-cycle compound and application thereof
IL285219A (en) A crystal of the compound diarylthiohydantoin
GB2574223B (en) Adhesives and methods of forming adhesives
IL263868A (en) Crystal structures of aminomethyl-converted tetracyclines and processes for their preparation
IL283703A (en) A polymorphic form of meisoindigo and a different formulation of meisoindigo
SG11202009262VA (en) Salts of compounds and crystals thereof
SG11202105136WA (en) Application of chidamide
EP3845534A4 (en) SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF
HK40055555A (en) Salts and crystal forms of omecamtiv mecarbil
IL290272B1 (en) Stable polymorphic form of -6 fluoro-9-methyl-9H-beta-carboline and its uses
GB201908573D0 (en) Compounds and methods of use
HK40062996A (en) Irreversible inhibitors of menin-mll interaction
HUP1600610A2 (en) Material composition primarily for plaster on inner side of walls; synthesis and application thereof